Armistice Capital, LLC has filed its 13F form on November 14, 2024 for Q3 2024 where it was disclosed a total value porftolio of $6.02 Billion distributed in 259 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Ptc Therapeutics, Inc. with a value of $268M, Supernus Pharmaceuticals, Inc. with a value of $159M, Incyte Corp with a value of $145M, Travere Therapeutics, Inc. with a value of $107M, and Cytokinetics Inc with a value of $100M.

Examining the 13F form we can see an decrease of $1.66B in the current position value, from $7.69B to 6.02B.

Armistice Capital, LLC is based out at New York, NY

Below you can find more details about Armistice Capital, LLC portfolio as well as his latest detailed transactions.

Portfolio value $6.02 Billion
Healthcare: $2.52 Billion
ETFs: $2.3 Billion
Consumer Cyclical: $446 Million
Consumer Defensive: $331 Million
Technology: $320 Million
Communication Services: $43.7 Million
Basic Materials: $31.2 Million
Energy: $20.9 Million
Other: $12.7 Million

Stock Holdings Table Companies Only

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 259
  • Current Value $6.02 Billion
  • Prior Value $7.69 Billion
  • Filing
  • Period Q3 2024
  • Filing Date November 14, 2024
  • Form Type 13F-HR
  • Activity in Q3 2024
  • New Purchases 79 stocks
  • Additional Purchases 85 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 62 stocks
Track This Portfolio

Track Armistice Capital, LLC Portfolio

Follow Armistice Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.